Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments are welcome to point out any issues. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.April 2025 to present, within and outside ChinaA series of eye-catching financing events have emerged in the CGT field, injecting new vitality into the industry's development. According to incomplete statistics, there were 10 financing events. In addition to the four companies we previously mentioned (Noway Biotech, Mitochon, Ruijian Medicine, and Everlife Stem Cell Company), six other companies have completed financing. (For related articles, please click to view.)Four CGT Companies Complete Financing, with the Highest Nearly 100 Million Yuan）1. Ophthalmology Gene Therapy Company Atsena Therapeutics Completes Series C Financing
April 2nd, Ophthalmic Gene Therapy DevelopmentCompanyAtsena Therapeutics Announces Successful CompletionSuccess $150 millionOversubscribed Series C Financing. This round of financing was led by Bain Capital（Bain Capita）Led by the life sciences team, another new investor, Wellington Management Company（Wellington Management）Also participated in this round of financing. All existing investors of the company participated in this round of financing.
This financing will be mainly used to advance the development of ATSN-201, one of Atsena's leading projects, which is aimed at treating X-linked retinoschisis.（XLRS）XLRS is a hereditary disease that primarily affects males and is usually diagnosed during childhood. It is characterized by abnormal splitting between retinal layers, with progressive vision loss occurring with age, eventually leading to blindness. The proceeds from this financing will also be used to support Atsena’s first-in-class preclinical pipeline therapies and expand the application of Atsena's novel diffusion-type capsid AAV.SPR.2. Anhui Zhongsheng Traceability Biotechnology Co., Ltd. Completes RMB 235 Million Series B FinancingIn April, Anhui Zhongsheng Traceability Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Traceability") announced that it had received tens of millions of yuan in funding support in its Series B round. Thus, Zhongsheng Traceability's Series B round has successfully concluded.The Cumulative Financing Amount in This Round Reaches 235 Million Yuan。This additional financing was jointly participated by well-known investment institutions such as Guangyao Capital, Sci-Tech Gold Holdings, Hefei Industrial Investment, and Hanyuan Assets. The funds will mainly be used to accelerate the development of multiple clinical pipelines in the iPSC-derived cell therapy field by Anhui Zhongsheng Traceability Biotechnology Co., Ltd. and the subsequent commercialization of its products.
3. Rigerna Completes Pre-A Round FinancingOn April 7, Rigerna announced the completion of the first closing of its Pre-A round financing. The first phase of this round's fundraising was invested by Jinyifu Xinxin and others. This market-oriented financing will be used to rapidly advance the clinical research of its core product RG002C0106, as well as the continued development of extrahepatic delivery technology and drug pipelines. This follows the company’s over 100-million-yuan angel+ round completed last year.FinancingLater, new financing was obtained.Rigerna was founded in 2022 and focuses on the research and development and industrialization of small nucleic acid drugs. The companyFirst Pipeline RG002C0106It is an siRNA drug developed targeting the complement factor C3.Intended for the treatment of primary or secondary glomerular diseases mediated by complement involvement. This product has demonstrated excellent efficacy and safety in preclinical studies, and is currently undergoing Phase 1 clinical trials, with Phase 2 clinical trials soon to be initiated.4. Rigerna Completes Tens of Millions of Yuan in Angel+ RoundApril,Saiyun Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as "Saiyun Bio")Announced the completion of tens of millions of angel+ round financing. This round of financing was led by a well-known hard technology investment institution.CAS StarExclusive investment, the raised funds will be mainly used to accelerate the development process of the company's self-developed pipeline.Rigerna is a company focused on the research and development of targeted delivery technologies and innovative drug therapies. It has successfully developed a class of biomimetic delivery systems with independent intellectual property rights, which are distinct from mainstream delivery carrier systems. Through rational modification, this system enables precise cellular delivery of various types of payloads and demonstrates significant advantages in specific recognition, payload compatibility, protection, and production costs.5. Rigerna Completes First Round of Financing
Mid-April,Qiselian (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Qiselian Biotech")Announced the completion byBioVeda China Fund (BVCF)The first round of exclusive investment will be mainly used to accelerate the construction of the company's platform and product development.Rigerna focuses on personalized cell therapy and anti-aging, developing innovative products and services for autologous cell treatment, regenerative medicine, and health management based on next-generation induced pluripotent stem cell (iPSC) technology. By building a standardized, large-scale high-quality cell resource platform, the company provides solid technical support for diverse application scenarios, driving the innovation process in cell therapy and anti-aging technology.6. Nanjing Yuanmai Cell BiotechnologyReceived New Round of FinancingIn mid-April, Nanjing Yuanmai Cell Biotechnology Co., Ltd. secured a new round of financing.RigernaFounded by the research team of Shen Pingping from Nanjing University and senior pharmaceutical executives, the company focuses on developing therapeutic technologies for fibrotic diseases and solid tumors, aiming to address unmet clinical needs. It has established four core technology platforms with independent intellectual property rights: a high-throughput screening system for anti-fibrotic payloads, a CAR functional module library, an in vitro gene editing system, and an in vivo gene editing delivery system. Through its in vivo gene editing delivery technology, Yuanmai Cell is advancing macrophage engineering from ex vivo transfection to in vivo editing, marking a transition from cell therapy to biopharmaceuticals. Its project targeting liver fibrosis is currently undergoing investigator-initiated clinical trials (IIT).Since April 2025, this series of financing events in the CGT field, from the breakthrough of ophthalmic gene therapy in treating rare diseases to the accelerated commercialization process of iPSC-derived cell therapy; from innovations in targeted delivery technology enhancing drug efficacy to the exploration of personalized cell therapy for new anti-aging directions. With the injection of funds and integration of resources, these companies will accelerate progress in R&D, clinical transformation, and commercialization.
Reference: Public Information
